The efficacy and safety of mismatched hematopoietic stem cell transplantation for treatment of severe aplastic anemia
10.3760/cma.j.issn.0578-1426.2011.04.006
- VernacularTitle:配型不合造血干细胞移植治疗重型再生障碍性贫血的疗效及安全性
- Author:
Wei HAN
;
Xiaojun HUANG
;
Kaiyan LIU
;
Lanping XU
;
Daihong LIU
;
Huan CHEN
;
Xiaohui ZHANG
;
Yuhong CHEN
;
Fengrong WANG
;
Yu WANG
- Publication Type:Journal Article
- Keywords:
Anemia,aplastic;
Stem cell transplantation,hematopoietic;
HLA antigens;
Mismatched typing
- From:
Chinese Journal of Internal Medicine
2011;50(4):287-290
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of human leukocyte antigen (HLA)mismatched hematopoietic stem cell transplantation (HSCT) on severe aplastic anemia(SAA). Methods From January 2006 to May 2010, 17 patients received mismatched HSCT. HLA antigens were 3-locimismatched in 9 patients, 2-loci-mismatched in 8. All patients received recombinant human granulocyte colony-stimulating factor (rhG-CSF) primed bone marrow cells plus peripheral blood stem cells after modified busulfan/cyclophosphamide + antithymocyte immunoglobulin (BU/CY + ATG ) conditioning regimen. Results All patients achieved full donor type engraftment. Grade Ⅲ-Ⅳ graft versus host disease (GVHD) occurred in 3 patients and extensive chronic GVHD in 1. With a median following-up time of 285(60-1670) d, 11 patients were alive, 9 of them had normal blood counts and the other 2 were blood transfusion independent. Six patients died of transplant-related complications. Conclusion Mismatched HSCT is a feasible and safe option for SAA patients without sibling identical donors.
